Journal article
Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions in Double-Blind Clinical Trials
Journal of investigative dermatology, Vol.73(4), pp.261-263
10/1979
DOI: 10.1111/1523-1747.ep12531617
PMID: 383851
Abstract
Two double-blind studies comparing the effectiveness of the cyclic nucleotide-attering agent (4-[3-butoxy-4-methoxybenzyl]-2-imidazolidinone) (Ro 20-1724) vs vehicle have demonstrated that this compound can improve psoriatic lesions. Although Ro 20-1724 was not as effective as intensive occlusive treatment of psoriatic lesions with 0.025% triameinolone acetonide, Ro 20-1724 had no adverse systemic or cutaneous effects. Ro 20-1724 and other cyclic nucleotide-altering agents may have therapeutic potential in the future treatment of psoriasis.
Details
- Title: Subtitle
- Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions in Double-Blind Clinical Trials
- Creators
- Marek A. Stawiski - University of Michigan–Ann ArborLouis J. Rusin - University of Michigan–Ann ArborTrudy L. Burns - University of Michigan–Ann ArborGerald D. Weinstein - University of MiamiJohn J. Voorhees - University of Michigan–Ann Arbor
- Resource Type
- Journal article
- Publication Details
- Journal of investigative dermatology, Vol.73(4), pp.261-263
- Publisher
- Elsevier Inc
- DOI
- 10.1111/1523-1747.ep12531617
- PMID
- 383851
- ISSN
- 0022-202X
- eISSN
- 1523-1747
- Language
- English
- Date published
- 10/1979
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984363614402771
Metrics
11 Record Views